MS Australia

Last updated

Multiple Sclerosis Australia, commonly referred to as MS Australia, is a prominent national non-profit organization with a primary focus on research and advocacy in support of individuals affected by Multiple Sclerosis (MS). This organization achieved official registration as a charitable entity in Australia in the year 1975. [1] As of July 2021, there are over 25,000 people living with multiple sclerosis in Australia [2] and MS Australia serves as the peak body for all Australians living with or otherwise affected by MS. [3]

Contents

The organisation characterises its approach as one that leverages Australia's unique strengths within the broader global landscape of Multiple Sclerosis (MS) research. MS Australia is committed to fostering the Australian MS research network while actively pursuing several overarching research objectives. These research objectives encompass:

MS Australia encourages a national collaborative effort into MS research. The organisation seeks to enable researchers to make discoveries not possible when working alone by inviting individual research teams to apply for support while also supporting major platform' projects. There are numerous instances of MS Australia providing research grants to individual researchers or research teams. [5] [6] [7]

David Hurley, Governor-General of Australia (2019- ), is the current patron of MS Australia.

Founding

MS Australia was first established as the Australian MS Society in 1956, with the first general meeting held in February 1957. Nine years earlier, in 1947, American Sylvia Lawry founded the National Multiple Sclerosis Society in New York in the United States, and co-founded the Multiple Sclerosis International Federation the same year. Soon after followed the establishment of the Multiple Sclerosis Society of Canada in 1948 and the Multiple Sclerosis Society of Great Britain in 1953. The Australian MS Society was therefore the fourth society globally to be established for multiple sclerosis support and advocacy. [8]

Activities

Research

MS research seeks to address the treatment and prevention of multiple sclerosis and the management of its many symptoms, as well as trying to find a cure. Research into MS encompasses immunology, neurology, genetics, and epidemiology, and extends across clinical and allied health disciplines.

In 2004, MS Australia established a subsidiary research branch called MS Research Australia. In June 2020, MS Research Australia was integrated into MS Australia as a fully integrated organisation under one CEO and Board.

MS Australia states that the organisation's medium to long term strategy focuses on funding research to better understand the biological basis of MS to prevent the disease from being triggered and causing further damage. Simultaneously, this research investigates how existing damage can be repaired to reverse disability.

MS Australia’s short-term strategy focuses on clinical research to measure the benefits of seeking alternative ways to manage MS symptoms. [9] The Australian MS Longitudinal Study (AMSLS) measures the physical, social and economic impact of MS on Australians for advocacy and service development purposes.

MS Australia currently approaches these strategies through several branches:

Research Achievements

MS Australia claims to have achieved the following through its funding and research efforts:

Advocacy

MS Australia describes their advocacy role for the MS community within Australia as comprising three levels:

Role in the National MS Community

MS Australia works with state MS bodies, connecting MS community members (including those living with the disease, family, friends, and carers) with support, information, and community. The organisation also advocates for these state bodies in communities and with the federal government. [24]

There are four state MS bodies:

MS Australia is also a partner of several Australian support and advocacy groups, such as Rare Voices Australia (RVA), a body which promotes the creation of an Australian National Rare Disease Plan. [25]

Alliances

MS Australia has close relationships with numerous community representative groups to build awareness of key issues for people with MS. [26] MS Australia is a member of the following alliances:

Submissions

MS Australia regularly seeks opportunities to contribute to policy development and government reviews by submitting proposals to the Australian government. These submissions range from those which propose a re-evaluation of cannabinoids by the Therapeutic Goods Administration to facilitate cannabinoid usage for people suffering from MS, to providing information for the National Disability Employment Strategy about key areas affecting people with MS. [27] [28] [29]

Role in the Global MS Community

MS Australia is involved with numerous international MS organizations. These include:

Multiple Sclerosis International Federation (MSIF)

The Multiple Sclerosis International Federation comprises 48 MS societies worldwide, including MS Australia. [30] Several MS Australia executive staff hold significant positions on the MSIF Board and fulfill MSIF committee roles.

MS Australia participates annually in World MS Day, which occurs on 30 May and is led by MSIF. Associated activities occur throughout May and early June and are designed to bring the global MS community together to raise awareness of the disease and campaign with all those affected by MS.

International Progressive MS Alliance

MS Australia is a managing member of the Alliance. Key staff are representatives on a variety of committees including the Executive Committee which is responsible for the oversight, strategic intent, and governance of the global collaborative, the Scientific Steering Committee, and the Fundraising and Communications committee.

The International MS Genetics Consortium [31]

MS Brain Health

MS Brain Health is an initiative calling for a radical change in the management of MS based on a 2015 report that discusses diagnosis, therapeutic strategies and improving access to treatment in MS. [32] MS Australia keenly endorses this initiative, and several key MS Australia personnel are directly involved with supporting the MS Brain Health global initiative. [33]

Related Research Articles

<span class="mw-page-title-main">Multiple sclerosis</span> Disease that damages the myelin sheaths around nerves

Multiple sclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. In the progressive forms of MS, bodily function slowly deteriorates and disability worsens once symptoms manifest and will steadily continue to do so if the disease is left untreated.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Interferon beta-1a</span> Cytokine in the interferon family

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses.

<span class="mw-page-title-main">National Alliance on Mental Illness</span> American nonprofit organization

The National Alliance on Mental Illness (NAMI) is a United States-based nonprofit organization originally founded as a grassroots group by family members of people diagnosed with mental illness. NAMI identifies its mission as "providing advocacy, education, support and public awareness so that all individuals and families affected by mental illness can build better lives" and its vision as "a world where all people affected by mental illness live healthy, fulfilling lives supported by a community that cares". NAMI offers classes and trainings for people living with mental illnesses, their families, community members, and professionals, including what is termed psychoeducation, or education about mental illness. NAMI holds regular events which combine fundraising for the organization and education, including Mental Illness Awareness Week and NAMIWalks.

The Multiple Sclerosis Society is the UK's largest charity for people affected by multiple sclerosis (MS). Based in London, it has offices and local groups in England, Northern Ireland, Scotland and Wales. It gained charitable company status in 2010.

<span class="mw-page-title-main">Nabiximols</span> Specific cannabis extract

Nabiximols is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019, it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.

The National Multiple Sclerosis Society (NMSS) is a nonprofit organization founded in 1946. It is an organization dedicated to supporting individuals affected by multiple sclerosis (MS) and funding research to find a cure for the disease. They provide resources, support services, advocacy efforts, and educational programs to improve the lives of people with MS and their families.

Intention tremor is a dyskinetic disorder characterized by a broad, coarse, and low-frequency tremor evident during deliberate and visually-guided movement. An intention tremor is usually perpendicular to the direction of movement. When experiencing an intention tremor, one often overshoots or undershoots one's target, a condition known as dysmetria. Intention tremor is the result of dysfunction of the cerebellum, particularly on the same side as the tremor in the lateral zone, which controls visually guided movements. Depending on the location of cerebellar damage, these tremors can be either unilateral or bilateral.

Low-dose naltrexone (LDN) describes the off-label, experimental use of the medication naltrexone at low doses for diseases such as Crohn's disease, Hashimoto's disease, and multiple sclerosis, but evidence for recommending such use is lacking.

<span class="mw-page-title-main">Multiple Sclerosis International Federation</span>

The Multiple Sclerosis International Federation (MSIF) was established in 1967 as an international body linking the activities of various national MS societies. The federation seeks to partner with member societies and the international scientific community to eliminate multiple sclerosis and its consequences, and to advocate for those affected by multiple sclerosis.

<span class="mw-page-title-main">Infectious Diseases Society of America</span> Medical association

The Infectious Diseases Society of America (IDSA) is a medical association representing physicians, scientists, and other healthcare professionals who specialize in infectious diseases. It was founded in 1963 and is based in Arlington, Virginia. As of 2018, IDSA had more than 11,000 members from across the United States and nearly 100 other countries on six different continents. IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. It is a 501(c)(6) organization.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.

The Shepherd Center is a private, non-profit hospital in Atlanta, Georgia. Founded in 1975, the hospital focuses on rehabilitation for people with spinal cord injury and disease, acquired brain injury, multiple sclerosis, chronic pain and other neuromuscular problems.

<span class="mw-page-title-main">Corinne Goldsmith Dickinson Center for Multiple Sclerosis</span>

The Corinne Goldsmith Dickinson Center for Multiple Sclerosis is a multiple sclerosis research and treatment center in New York City.

<span class="mw-page-title-main">Chronic cerebrospinal venous insufficiency controversy</span> Medical condition

Chronic cerebrospinal venous insufficiency is a term invented by Italian researcher Paolo Zamboni in 2008 to describe compromised flow of blood in the veins draining the central nervous system. Zamboni hypothesized that it might play a role in the cause or development of multiple sclerosis (MS). Zamboni also devised a surgical procedure which the media nicknamed a liberation procedure or liberation therapy, involving venoplasty or stenting of certain veins. Zamboni's ideas about CCSVI are very controversial, with significantly more detractors than supporters, and any treatments based on his ideas are considered experimental.

<span class="mw-page-title-main">Diagnosis of multiple sclerosis</span>

Current standards for diagnosing multiple sclerosis (MS) are based on the 2018 revision of McDonald criteria. They rely on MRI detection of demyelinating lesions in the CNS, which are distributed in space (DIS) and in time (DIT). It is also a requirement that any possible known disease that produces demyelinating lesions is ruled out before applying McDonald's criteria.

<span class="mw-page-title-main">Ponesimod</span> Medication for the treatment of multiple sclerosis

Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis. It is a sphingosine-1-phosphate receptor modulator.

Multiple Sclerosis Australia, or MS Australia, is a national non-profit organization in Australia that coordinates and allocates funds for multiple sclerosis research.

References

  1. ↑ "Multiple Sclerosis Australia". Australian Charities and Not-for-profits Commission. 2021-07-27. Archived from the original on 2021-07-26. Retrieved 2021-07-29.
  2. ↑ "Multiple sclerosis (MS)". Better Health Channel. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  3. ↑ "MS Australia". Australian Prescriber. 25 (2): 36–37. 2002-03-01. doi: 10.18773/austprescr.2002.035 . Archived from the original on 2022-02-20. Retrieved 2021-07-29.
  4. ↑ Cullen, Jessica (2021-06-24). "Prioritising the MS research and advocacy agenda – have your say!". MS Australia. Archived from the original on 2021-07-26. Retrieved 2021-07-29.
  5. ↑ "ANU awarded $200,000 for Multiple Sclerosis research". ANU College of Health & Medicine. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  6. ↑ "Stem cell research for new MS treatment". The University of Adelaide. 2013-05-10. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  7. ↑ "MS Research Australia funding to spur single-cell research". Garvan Institute of Medical Research. 2018-10-05. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  8. ↑ "Our first 60 years". MS Australia. Archived from the original on 2021-07-26. Retrieved 2021-07-28.
  9. ↑ "MS Research Australia's Project Grant for improving MS treatment". John Curtin School for Medical Research. 2021-01-20. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  10. ↑ "ANZgene". MS Research Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  11. ↑ "MS researchers to explore environmental triggers". The University of Newcastle, Australia. 2015-03-05. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  12. ↑ "MS Research Australia Brain Bank". MS Brain Bank. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  13. ↑ "Increasing Awareness for MS Trials". MS Trials. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  14. ↑ "Australian MS Longitudinal Study Overview". MS Research Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  15. ↑ "Proteomics of MS". MS Research Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  16. ↑ "Vitamin D MS Prevention Trial - PrevANZ". MS Research Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  17. ↑ "Australia rolls out world first MS prevention trial - Menzies Institute for Medical Research". Menzies Institute for Medical Research - University of Tasmania, Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  18. ↑ Scott, Sophie; Griffiths, Meredith (2017-02-03). "'Stunning breakthrough' helping to rapidly identify types of MS". ABC News. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  19. ↑ Mercer, Phil (2018-11-24). "Multiple Sclerosis Treatment Developed in Australia Shows Promise". Voice of America. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  20. ↑ Stevenson, Ashleigh (2018-11-20). "MS patients feel 'in control' again after immunotherapy trial". ABC News. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  21. ↑ "Beneficiaries". Hearts & Minds Investments. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  22. ↑ "Impacts and achievements". MS Research Australia. Archived from the original on 2021-07-27. Retrieved 2021-07-29.
  23. ↑ "Advocacy | MS Australia". Archived from the original on 2021-06-15. Retrieved 2021-07-27.
  24. ↑ "What We do | MS Australia". Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  25. ↑ "Multiple Sclerosis (MS) Australia - Rare Voices Australia". Rarevoices.org.au. Archived from the original on 2021-07-27. Retrieved 2022-02-20.
  26. ↑ "Alliances | MS Australia". Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  27. ↑ "MS Australia". engage.dss.gov.au. Archived from the original on 2021-07-30. Retrieved 2022-02-20.
  28. ↑ "Archived copy" (PDF). Archived (PDF) from the original on 2021-07-30. Retrieved 2021-07-30.{{cite web}}: CS1 maint: archived copy as title (link)
  29. ↑ "Archived copy" (PDF). Archived (PDF) from the original on 2021-07-30. Retrieved 2021-07-30.{{cite web}}: CS1 maint: archived copy as title (link)
  30. ↑ "MS Australia puts Women's Health in the spotlight". MS International Federation. 2020-11-09. Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  31. ↑ "Research networks - MS Research Australia". Archived from the original on 2021-07-27. Retrieved 2021-07-27.
  32. ↑ "Vision and mission - MS Brain Health - Multiple Sclerosis Brain Health initiative". MS Brain Health. Archived from the original on 2021-07-20. Retrieved 2022-02-20.
  33. ↑ "MS Brain Health". MS Research Australia. Archived from the original on 27 July 2021. Retrieved 30 July 2021./ Archived 2021-07-27 at the Wayback Machine
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.